Common questions about Aurovela (FAQ)
Q: What are the most commonly reported side effects of Aurovela?
According to official product information, common adverse reactions may include headache, nausea, vaginal candidiasis, menstrual cramps, breast tenderness or pain, mood changes, irregular uterine bleeding (spotting or breakthrough bleeding), acne, and weight fluctuation. These reactions are typically reported in a small percentage of users.
Q: Can certain antibiotics make Aurovela less effective?
Regulatory documents state that certain antibiotics may interact with the hormones in Aurovela. Anti-tuberculosis medications, such as rifampin, can significantly decrease the level of the contraceptive hormones. Other agents, including certain penicillins and tetracyclines, are also noted as substances that may possibly reduce the overall efficacy.
Q: Is it true that Aurovela contains two different hormones?
Yes, Aurovela is officially classified as a combination oral contraceptive. It contains two active hormones: an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate).
Q: Is Aurovela used for treating conditions other than birth control?
In addition to preventing pregnancy, the official labeling indicates that this medicine may also be used for the treatment of moderate acne vulgaris. This is specifically for women who are seeking an oral contraceptive for birth control.
Q: What is the clinical evidence supporting the use of Aurovela?
Clinical trials for combination oral contraceptives in this class track the rate of pregnancy in observed populations when the regimen was followed under specific trial conditions. Studies report patterns related to success in preventing pregnancy when the medication is used exactly as prescribed.
Q: Does taking Aurovela cause weight gain?
The official safety profile lists weight fluctuation as a commonly reported adverse reaction. This may include either weight gain or weight loss, as documented in clinical trial data.
Q: What happens if I miss a period while on Aurovela?
The regulatory documents advise that if two periods in a row are missed, the possibility of pregnancy is generally advised to be ruled out by a healthcare provider before continued use. If the dosing schedule has not been strictly followed, pregnancy should be considered at the time of the first missed period.
Q: What should I do if my period gets significantly heavier or lighter on Aurovela?
Changes in menstrual flow are a common occurrence. However, if severe or continuous changes, such as very heavy bleeding or persistent spotting, occur, official safety information advises that such events are generally reviewed by a healthcare provider.
Q: Does Aurovela offer protection against sexually transmitted infections?
No. The official labeling is clear that this medicine is designed to prevent pregnancy only. It does not protect against HIV infection (AIDS) or other sexually transmitted diseases (STDs).
Q: Can Aurovela cause changes in vision or headaches?
Headache is a commonly reported side effect. Rarely, serious events related to vision have been reported. The label notes that severe or sudden vision changes are factors that are typically assessed immediately by a healthcare provider.
Q: Do regulatory documents mention any risks for users with diabetes?
Yes, official safety information states that prediabetic and diabetic women should be carefully observed while using the medication. This is due to the potential for oral contraceptives to affect blood glucose and lipid metabolism.
Q: Does Aurovela have a generic version available?
Aurovela is itself a generic form of a combination oral contraceptive. There are other FDA-approved generic products that contain the same active hormonal ingredients and strengths.
Q: How quickly does Aurovela start working for its intended purpose?
If you begin taking the medicine on the first day of your menstrual period, contraceptive protection starts immediately. If you start on the first Sunday after your period, official guidance requires the use of a non-hormonal back-up method for the first seven consecutive days to prevent pregnancy.
Q: How is Aurovela different from other similar medicines?
Aurovela is classified as a monophasic combination oral contraceptive. This means that every active tablet contains a fixed, single dose of both estrogen and progestin, which distinguishes it from multiphasic pills that vary the hormone levels throughout the cycle.
Q: Is it normal to have light bleeding when starting Aurovela?
Yes, light bleeding between periods, known as spotting or breakthrough bleeding, is a commonly reported side effect. Official documents note that this is especially common during the first few months as the body adjusts to the medicine.
Q: Can Aurovela affect my mood or emotional state?
Mood changes, including anxiety and depression, are listed among the commonly reported adverse reactions associated with this medication according to the official safety profile.
Q: Are there any long-term effects associated with taking Aurovela?
The official warnings discuss that the risk of serious conditions like venous thromboembolism is highest during the first year of use. Additionally, some studies have examined and discussed a potentially raised risk of cervical cancer associated with long-term use.
Q: Can I take Aurovela if I have a history of migraines?
Regulatory documents list severe headaches and migraines as a health factor that may require careful observation. If the headaches are new, severe, or are accompanied by neurological symptoms, such factors are typically assessed and reviewed by a healthcare professional prior to use.
Q: What food or supplements should be avoided while on Aurovela?
Official drug interaction lists note that consumption of grapefruit juice may increase the concentration of the hormones in your blood. The herbal supplement St. John’s Wort is also listed as an interacting substance that can decrease the medicine's efficacy.
Q: How long does it take for Aurovela to leave my system after I stop taking it?
After stopping the medication, the return of normal fertility is the expected process. However, the official safety profile mentions that some women may experience a temporary delay in the return of their normal menstrual cycle and fertility.
Q: Will Aurovela affect the results of any lab tests?
Yes, regulatory documents indicate that this medication may interfere with the results of certain laboratory tests. These include tests for blood clotting factors and thyroid function, which could potentially lead to inaccurate results.
Q: Are there any studies looking at the effects of Aurovela on future fertility?
While research primarily focuses on the medicine's immediate effect, the official safety profile acknowledges the possibility of temporary infertility after discontinuation of treatment. Fertility is expected to return after stopping the medicine.
Q: Is it safe to drive or operate machinery while taking Aurovela?
The official label does not include a specific warning against driving or operating machinery. However, commonly reported side effects such as headache, dizziness, and lightheadedness could potentially affect a person’s ability to perform these activities.
Q: How is the progesterone component of Aurovela described?
The progesterone component is chemically known as norethindrone acetate. This substance is classified as a synthetic progestin.
Q: Do all versions of Aurovela contain the same active ingredients?
Yes. All versions of Aurovela contain the same two active hormonal ingredients—norethindrone acetate and ethinyl estradiol. They differ only in the dosage strength of these hormones.
Q: Are there different brand names that contain the same formulation as Aurovela?
Yes, the FDA has approved several other brand names that contain the exact same active hormonal formulation and strengths. Examples include Loestrin Fe, Microgestin Fe, and Junel Fe.
Q: Is there a difference in how Aurovela works compared to a progestin-only pill?
Aurovela is a combination pill that includes estrogen, which works primarily to suppress ovulation (release of the egg) in addition to thickening cervical mucus. Progestin-only pills rely mainly on altering cervical mucus and the uterine lining, and do not consistently suppress ovulation.
Q: What if I start taking Aurovela mid-cycle?
Official starting methods are Day 1 or Sunday. If the medication is started at any other time, or outside of the first five days of your period, regulatory guidance requires the use of a back-up, non-hormonal contraceptive method for the first seven days to maintain efficacy.
Q: Is it normal to feel bloated when first using Aurovela?
Yes, according to the official safety profile, bloating and abdominal cramps are listed among the commonly reported adverse reactions for this medicine.
Q: Does being overweight or obese change how Aurovela works?
The official labeling states that the efficacy of the medicine has not been evaluated in clinical trials for women with a Body Mass Index (BMI) greater than 35 kg/m^2. This means there is limited research for this specific population.
Q: What is the difference between Aurovela 1/20 and Aurovela 1.5/30?
The difference is in the strength of the hormones contained in each active pill. The 1/20 version has a lower dose of both the progestin and the estrogen than the 1.5/30 version.
Q: Can I take Aurovela while breastfeeding?
Official recommendations state that this medicine is generally not advised for use in breastfeeding women. The contraceptive hormones are known to be excreted in human milk and can potentially reduce the mother's milk production.
Q: Why do some people report changes in skin when taking Aurovela?
Changes in skin, such as acne, are listed as a common adverse reaction. Since the medicine contains hormones, this effect is thought to be related to the hormonal balance influencing skin receptors. The medicine is sometimes prescribed to address acne.
Q: Is it still effective if I have vomiting or severe diarrhea?
Vomiting or acute diarrhea occurring shortly after taking an active tablet can be treated as a missed dose. The official instructions indicate that this scenario is treated as a missed dose. Efficacy may be reduced, and specific guidance related to the missed dose procedures is described in the product information.
